CASTRES, France, November 17, 2026
Laboratoires Pierre Fabre announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to elticertinib (PFL-721, formerly STX-721) for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations (EGFR ex20ins) whose disease has progressed following platinum-based chemotherapy and amivantamab. The regulatory designation represents an important milestone in the development of this investigational targeted therapy and highlights continued efforts to address unmet medical needs in patients with advanced lung cancer. Fast Track status is designed to facilitate the development and expedite the review of therapies intended to treat serious conditions where significant unmet medical needs remain, providing drug developers with enhanced opportunities for communication and collaboration with the FDA throughout the clinical development and regulatory process.
FDA Fast Track Supports Accelerated Drug Development
The FDA’s Fast Track designation is intended to accelerate the development and review of investigational medicines targeting serious diseases with substantial unmet medical needs. Under this pathway, Laboratoires Pierre Fabre may benefit from more frequent interactions with the FDA, enabling discussions regarding clinical development strategies, regulatory requirements, and evidence generation. The designation also provides the potential for rolling review and priority review, subject to the applicable eligibility criteria and regulatory requirements. The designation was granted based on nonclinical data and preliminary efficacy findings from the ongoing Phase 1/2 clinical trial (NCT06043817). Although Fast Track designation does not constitute marketing approval, it can support more efficient communication between the sponsor and regulatory authorities as clinical development progresses and additional evidence is generated regarding the investigational therapy’s safety and efficacy.
Elticertinib Targets EGFR and HER2 Exon 20 Mutations
Elticertinib is an investigational, orally available, irreversible, highly selective tyrosine kinase inhibitor (TKI) designed to target EGFR and ERBB2 (HER2) exon 20 insertion mutations. These genetic alterations are associated with oncogenic signaling pathways that contribute to cancer development and progression. By selectively targeting mutation-associated kinase activity, elticertinib is being developed as a precision oncology approach for patients with NSCLC whose tumors carry specific molecular alterations. NSCLC represents the most common subtype of lung cancer, while EGFR mutations are among the major molecular drivers identified in the disease. Their prevalence varies geographically, with EGFR alterations reported in up to 38% of lung cancer tumors in certain populations. Among patients with EGFR-mutated NSCLC, exon 20 insertion mutations represent a distinct molecular subgroup, accounting for up to 10% of EGFR-mutated cases. These mutations can present therapeutic challenges and underscore the need for targeted treatment strategies designed to address specific tumor biology.
Addressing Unmet Needs in Advanced Lung Cancer
Patients with EGFR exon 20 insertion-mutated NSCLC continue to face treatment challenges, particularly when their disease progresses following previous therapies. The availability of treatment options may be limited by response durability, treatment-related tolerability, and disease progression, creating a need for new targeted approaches. According to Laboratoires Pierre Fabre, the Fast Track designation reinforces the importance of advancing elticertinib as a potential treatment option for this patient population. The company highlighted the designation as a milestone in its oncology research and development capabilities and its broader ambition to strengthen its position in precision oncology. The ongoing Phase 1/2 clinical program will be important in generating further clinical evidence to characterize elticertinib’s safety, efficacy, and potential therapeutic role in patients with advanced NSCLC carrying EGFR exon 20 insertion mutations. The designation also enables closer engagement with the FDA as development progresses, supporting efforts to advance the investigational treatment toward potential future regulatory milestones. While elticertinib remains under clinical investigation, the Fast Track designation reflects continued momentum in the development of molecularly targeted therapies for difficult-to-treat lung cancers.
Source: Laboratoires Pierre Fabre press release



